RT Journal Article
T1 MixInYeast: A Multicenter Study on Mixed Yeast Infections.
A1 Medina, Narda
A1 Soto-Debrán, Juan Carlos
A1 Seidel, Danila
A1 Akyar, Isin
A1 Badali, Hamid
A1 Barac, Aleksandra
A1 Bretagne, Stéphane
A1 Cag, Yasemin
A1 Cassagne, Carole
A1 Castro, Carmen
A1 Chakrabarti, Arunaloke
A1 Dannaoui, Eric
A1 Cardozo, Celia
A1 Garcia-Rodriguez, Julio
A1 Guitard, Juliette
A1 Hamal, Petr
A1 Hoenigl, Martin
A1 Jagielski, Tomasz
A1 Khodavaisy, Sadegh
A1 Lo Cascio, Giuliana
A1 Martínez-Rubio, María Carmen
A1 Meletiadis, Joseph
A1 Muñoz, Patricia
A1 Ochman, Elżbieta
A1 Peláez, Teresa
A1 Perez-Ayala Balzola, Ana
A1 Prattes, Juergen
A1 Roilides, Emmanuel
A1 Ruíz-Pérez de Pipaón, Maite
A1 Stauf, Raphael
A1 Steinmann, Jörg
A1 Suárez-Barrenechea, Ana Isabel
A1 Tejero, Rocío
A1 Trovato, Laura
A1 Viñuela, Lourdes
A1 Wongsuk, Thanwa
A1 Żak, Iwona
A1 Zarrinfar, Hossein
A1 Lass-Flörl, Cornelia
A1 Arikan-Akdagli, Sevtap
A1 Alastruey-Izquierdo, Ana
K1 Candida
K1 chrome agar
K1 invasive candidiasis
K1 mix infections
K1 polymicrobial infections
K1 yeast
AB Invasive candidiasis remains one of the most prevalent systemic mycoses, and several studies have documented the presence of mixed yeast (MY) infections. Here, we describe the epidemiology, clinical, and microbiological characteristics of MY infections causing invasive candidiasis in a multicenter prospective study. Thirty-four centers from 14 countries participated. Samples were collected in each center between April to September 2018, and they were sent to a reference center to confirm identification by sequencing methods and to perform antifungal susceptibility testing, according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST). A total of 6895 yeast cultures were identified and MY occurred in 150 cases (2.2%). Europe accounted for the highest number of centers, with an overall MY rate of 4.2% (118 out of 2840 yeast cultures). Of 122 MY cases, the most frequent combinations were Candida albicans/C. glabrata (42, 34.4%), C. albicans/C. parapsilosis (17, 14%), and C. glabrata/C. tropicalis (8, 6.5%). All Candida isolates were susceptible to amphotericin B, 6.4% were fluconazole-resistant, and two isolates (1.6%) were echinocandin-resistant. Accurate identification of the species involved in MY infections is essential to guide treatment decisions.
YR 2020
FD 2020-12-29
LK http://hdl.handle.net/10668/16883
UL http://hdl.handle.net/10668/16883
LA en
DS RISalud
RD Apr 7, 2025